Skip to main content
Explore URMC
menu

PMLT21055 / APEC1621D / Angela Girvin

Research Question:
Does the drug LY3023414 help patients with cancers that have spread to other places in the body and do not respond to treatment?

Basic Study Information

Purpose:
This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body (metastatic) and have come back (recurrent) or do not respond to treatment (refractory). Samotolisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Location: University of Rochester

Lead Researcher (Principal Investigator)

Lead Researcher:  Angela Girvin

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search